Empowered Patient Podcast

Fady Boctor, President and Chief Commercial Officer of Petros Pharmaceuticals, discusses the process of transitioning drugs from prescription to over-the-counter status, which includes conducting studies to determine label comprehension.  In this situation, the FDA reviews the package wording to determine if the consumer can self-select the drug safely without a physician's involvement. With a focus on men's health issues like erectile dysfunction, Petros also sees the opportunity to educate consumers, reduce healthcare costs, and potentially identify related conditions that might require further investigation. Fady explains, "Switches had been occurring, those prescriptions to OTC switches, have been occurring since really 1974, 1975. Over the past many years, about 106 products have been switched from prescription to OTC. The common denominator among those switches is that they're relatively safe products. We're talking antihistamines, allergy medications, and smoking cessation products. These are products